Sarcopenia Market Insight, Epidemiology And Market Forecast - 2032
상품코드:1415493
리서치사:DelveInsight
발행일:2023년 12월
페이지 정보:영문 136 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
사코페니아 시장 규모는 예측 기간(2023-2032년) 동안 안정적인 성장세를 보일 것으로 예상됩니다. 주요 7개국에서 사코페니아 시장 규모는 더 나은 진단과 새로운 치료법의 출시로 인해 확대될 것으로 예상됩니다. 주요 7개국에서 사코페니아으로 진단된 전체 환자 중 약 55%가 미국에서 발생할 것으로 예측됩니다. 2022년에는 EU 4개국과 영국에서 약 700만 명의 사코페니아 유병자가 진단을 받았습니다. 주요 7개국에서 시장은 주로 지지요법(비타민D, 호르몬 요법, 기타 적응증 외 약물 사용)과 같은 표준 치료로 구성되며, 2022년 약 27억 3,100만 달러 규모의 시장을 창출했습니다.
사코페니아은 골격근량, 근력 및 기능의 점진적인 감소를 특징으로 하는 노화 관련 질환입니다. 근육의 양과 질이 감소하는 것은 노화에 따른 자연스러운 현상이지만, 사코페니아은 이 현상이 가속화되어 병적으로 나타나는 것입니다. 발병 요인으로는 호르몬 변화, 신체 활동 감소, 영양 부족, 만성 질환 등을 들 수 있습니다. 사코페니아은 운동 능력 저하, 낙상 및 골절에 대한 감수성 증가, 전반적인 삶의 질 저하를 가져옵니다.
사코페니아 진단을 위해서는 임상 평가, 근육량 측정, 기능 검사 등을 포함한 종합적인 평가가 필요합니다. 유일한 진단 기준은 없지만 일반적인 방법으로는 이중 에너지 X선 흡수 측정법(DXA), 생체 전기 임피던스 분석법(BIA), 근육량을 정량화하는 자기공명영상법(MRI) 등이 있습니다. 또한 기능적 능력을 평가하기 위해 보행 속도, 의자 서기, 악력과 같은 신체 능력 검사를 자주 사용합니다. 진단은 개인의 나이, 성별, 전반적인 건강 상태를 고려하여 근육량과 기능을 확립된 기준치와 비교합니다. 이러한 다양한 지표를 통합하면 사코페니아의 존재와 심각성을 종합적으로 이해하고 적절한 중재 및 관리 전략을 안내할 수 있습니다.
주요 7개국의 사코페니아 시장 규모는 2022년 27억 3,100만 달러에 달했습니다. 그 중 미국이 65%에 육박하는 가장 큰 점유율을 차지하고 있습니다.
이 보고서는 주요 7개국의 사코페니아 시장을 조사했으며, 시장 개요와 함께 역학, 환자 동향, 새로운 치료법, 2032년까지 시장 규모 예측, 의료 미충족 수요 등을 제공합니다.
목차
제1장 주요 인사이트
제2장 보고서 서론
제3장 사코페니아 시장 개요
제4장 사코페니아 역학과 시장 조사 방법
제5장 사코페니아 주요 요약
제6장 주요 이벤트
제7장 사코페니아 질환의 배경과 개요
서론
정의와 분류
원인
위험 요인
병태생리학
바이오마커
기타 질환 상태와의 관련성
진단
치료와 관리
제8장 역학과 환자수
주요 조사 결과
전제조건과 이론적 근거 : 주요 7개국
주요 7개국 사코페니아 유병 진단 증례 총수
미국
EU 4개국과 영국
일본
제9장 사코페니아 환자 동향
제10장 신흥 약제
제11장 사코페니아 : 시장 분석
주요 조사 결과
주요 시장 예측의 전제조건
시장 전망
콘조인트 분석
주요 7개국의 사코페니아 전체 시장 규모
주요 7개국의 사코페니아 시장 규모, 치료법별
미국의 사코페니아 시장 규모
EU 4개국 및 영국의 사코페니아 시장 규모
일본의 사코페니아 시장 규모
제12장 주요 업계 리더의 견해
제13장 SWOT 분석
제14장 미충족 요구
제15장 시장 접근과 상환
미국
EU 4개국과 영국
일본
제16장 부록
제17장 DelveInsight의 서비스 내용
제18장 면책사항
LSH
영문 목차
영문목차
Key Highlights:
The Sarcopenia market is projected to witness consistent growth throughout the forecast period (2023-2032). The market size of Sarcopenia in the 7MM is expected to increase, driven by better diagnosis and the launch of emerging therapies.
DelveInsight's analyst projects that among the total diagnosed prevalent cases of Sarcopenia in 7MM approximately 55% of cases were from the US. As per our estimations, in 2022, EU4 and the UK accounted for around 7 million diagnosed prevalent cases of Sarcopenia.
In the 7MM, the market mainly consisted of standard treatments like supportive care (vitamin D, hormone therapies, and other off-label use of drugs) which generated nearly USD 2,731 million in 2022.
The total market size of the Sarcopenia treatment market is anticipated to experience growth during the forecast period due to the emergence of new and effective treatments, namely, Sarconeos (BIO101) and MYMD-1.
DelveInsight's "Sarcopenia - Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Sarcopenia, historical and forecasted epidemiology and the Sarcopenia market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
The Sarcopenia market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM Sarcopenia market size from 2019 to 2032. The report also covers current Sarcopenia treatment practices/algorithms and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Geography Covered:
The United States
EU4 (Germany, France, Italy, and Spain) and the United Kingdom
Japan
Study Period: 2019-2032.
Disease Understanding and Treatment Algorithm
Sarcopenia Overview
Sarcopenia is an age-related condition marked by the progressive loss of skeletal muscle mass, strength, and function. While a decline in muscle mass and quality is a natural part of aging, sarcopenia signifies an accelerated and pathological manifestation of this phenomenon. Factors contributing to its onset include hormonal changes, reduced physical activity, insufficient nutrition, and chronic illnesses. Sarcopenia can result in decreased mobility, heightened susceptibility to falls and fractures, and an overall diminished quality of life.
Sarcopenia Diagnosis
Diagnosing sarcopenia involves a comprehensive assessment that includes clinical evaluation, muscle mass measurement, and functional testing. While there is no single definitive diagnostic criterion, common methods include dual-energy X-ray absorptiometry (DXA), bioelectrical impedance analysis (BIA), and magnetic resonance imaging (MRI) to quantify muscle mass. Additionally, physical performance tests like gait speed, chair stands, and grip strength are often employed to assess functional capacity. The diagnosis considers an individual's age, gender, and overall health, comparing muscle mass and function to established reference values. Integrating these diverse measures provides a holistic understanding of the presence and severity of sarcopenia, guiding appropriate interventions and management strategies.
Sarcopenia Treatment
The treatment of sarcopenia typically involves a multifaceted approach addressing both lifestyle and medical factors. Resistance training exercises, focusing on progressive strength training, are central to improving muscle mass and function. Adequate protein intake, along with balanced nutrition, plays a crucial role in supporting muscle health. Vitamin D and calcium supplementation may be recommended, especially if deficiencies are identified.
In some cases, hormone replacement therapies and medications targeting muscle function and overall health may be considered. A personalized treatment plan, tailored to the individual's specific needs and underlying health conditions, is essential for effectively managing sarcopenia and promoting functional independence in older adults. Regular monitoring and adjustments to the treatment plan are often necessary to optimize outcomes.
Sarcopenia Epidemiology
As the market is derived using the patient-based model, the Sarcopenia epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Cases of Sarcopenia, Gender-specific Diagnosed Prevalent cases of Sarcopenia, Age-specific Diagnosed Prevalent cases of Sarcopenia, and Severity-specific Diagnosed Prevalent cases of Sarcopenia in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan, from 2019 to 2032. As per DelveInsight's estimations, the total diagnosed prevalent cases of Sarcopenia in the 7MM was approximately 27 million in 2022 and are projected to increase during the forecast period.
The overall count of individuals diagnosed with Sarcopenia in the US was approximately 15 million in 2022, and it is expected to increase at an estimated CAGR throughout the study period (2019-2023).
Among EU4 and the UK, France had the highest diagnosed prevalent population of Sarcopenia, with 2 million cases, followed by Italy and the UK in 2022. On the other hand, Spain had the lowest diagnosed prevalent population in the European region in 2022.
In 2022, Japan reported around 5 million diagnosed prevalent cases of Sarcopenia, with expectations of a modest rise in these cases.
Gender-specific diagnosed prevalent cases of Sarcopenia showed that males were more affected by Sarcopenia than females in the 7MM in 2022.
As per DelveInsight's analysis, the diagnosed prevalent cases of Sarcopenia based on age were categorized into three groups: 65-69 years, 70-79 years, and =80 years. The highest proportion of Sarcopenia cases was estimated in the 70-79 years age group in the 7MM, while the least cases were in the age group 65-69 years.
The cases of Sarcopenia were classified based on severity levels, including Mild-to-Moderate and severe. DelveInsight's estimations reveal that, higher number of severity-specific cases in the 7MM was attributed to Mild-to-Moderate cases, totaling 22 million.
Sarcopenia Drug Chapters
The drug chapter segment of the Sarcopenia report encloses a detailed analysis of Sarcopenia marketed drugs and mid-late stage (Phase III and Phase II) pipeline drugs. It also understands Sarcopenia clinical trial details, expressive pharmacological action, agreements and collaborations, approval, and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.
Emerging Drugs
Sarconeos (BIO101): Biophytis
Biophytis is developing Sarconeos (BIO101), an orally administered small molecule for neuromuscular diseases. Activating the MAS receptor in muscle cells, Sarconeos enhances biological resilience, preserving muscle function in age-related and wasting conditions. The MAS receptor is crucial in the Renin-Angiotensin System, regulating physiological functions. Positive Phase II results demonstrate improved gait speed and safety over 9 months. Anticipated global collaborations aim to advance BIO101 to Phase III, potentially addressing the unmet need in sarcopenia treatment and transforming this therapeutic field.
MYMD-1: MyMD Pharmaceuticals, Inc.
MYMD-1 is a novel therapeutic designed to address aging-related conditions such as sarcopenia and depression, particularly in the context of age or inflammatory-related diseases. Additionally, it demonstrates promise as an antifibrotic and antiprolific treatment. Functioning as a next-generation TNF-alpha inhibitor, MYMD-1 is administered orally, offering a more convenient and safer alternative compared to existing anti-TNF therapies. This innovation holds potential to provide meaningful therapeutic solutions for patients not effectively served by current TNF-alpha inhibitors.
Note: Detailed emerging therapies assessment will be provided in the final report of Sarcopenia.
Sarcopenia Market Outlook
Sarcopenia treatment can be broadly classified into lifestyle interventions, nutritional strategies, and, in some cases, pharmacological approaches. Lifestyle interventions primarily focus on resistance training exercises to improve muscle mass and strength. Nutritional strategies involve ensuring an adequate intake of protein and other essential nutrients crucial for muscle health. Pharmacological approaches may include hormone replacement therapies, such as testosterone or growth hormone, as well as emerging drug candidates targeting muscle function. The classification and selection of treatment modalities depend on the severity of sarcopenia, underlying health conditions, and individual patient characteristics, emphasizing a comprehensive and personalized approach to effectively manage this age-related condition.
The market for Sarcopenia is expected to experience positive growth with the approval of potential drugs like Sarconeos (BIO101) and MYMD-1.
The Sarcopenia market's total size in the 7MM reached approximately USD 2,731 million in 2022. Projections indicate a substantial growth during the forecast period.
Out of the 7MM, the United States dominated the market in 2022, representing the largest share at nearly 65%.
In 2022, EU4 and the UK captured an estimated USD 530 million, which is anticipated to increase at a substantial CAGR. Among the European countries, France covered the largest market share in 2022, followed by Italy, and the UK.
Japan alone represented approximately 16% of the total Sarcopenia market in 2022, projected to increase at a substantial CAGR during the study period.
The total market size of the Sarcopenia treatment market is anticipated to experience growth during the forecast period due to the emergence of new and effective treatments.
Sarcopenia Drugs Uptake
This section focuses on the uptake rate of potential drugs expected to launch in the market during 2019-2032. For example, Sarconeos (BIO101) in the US is expected to be launched by 2027.
Further detailed analysis of emerging therapies drug uptake in the report…
Sarcopenia Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase III, Phase II, and Phase I stage. It also analyzes key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Sarcopenia emerging therapies.
KOL Views
To keep up with current market trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate the secondary research. Industry Experts were contacted for insights on Sarcopenia evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake along with challenges related to accessibility, including KOL from University of Maryland School of Medicine, Baltimore, Maryland; Division of General Internal, Medicine and Geriatric Medicine, Albuquerque, New Mexico; Center for Geriatric Medicine, University Heidelberg, Agaplesion Bethanien Krankenhaus, Heidelberg; Department of Epidemiology, University of Oxford; Tokyo Metropolitan Institute of Gerontology, Tokyo, and others.
DelveInsight's analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Their opinion helps understand and validate current and emerging therapies, treatment patterns, or Sarcopenia market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.
Qualitative Analysis
We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.
Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.
Further, the therapies' safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.
Market Access and Reimbursement
The high cost of therapies for the treatment is a major factor restraining the growth of the global drug market. Because of the high cost, the economic burden is increasing, leading the patient to escape from proper treatment.
The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.
Scope of the Report:
The report covers a segment of key events, an executive summary, descriptive overview of Sarcopenia, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and treatment guidelines.
Additionally, an all-inclusive account of the current and emerging therapies and the elaborative profiles of late-stage and prominent therapies will impact the current treatment landscape.
A detailed review of the Sarcopenia market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind the approach is included in the report covering the 7MM drug outreach.
The report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help shape and drive the 7MM Sarcopenia market.
Sarcopenia Report Insights
Patient Population
Therapeutic Approaches
Sarcopenia Pipeline Analysis
Sarcopenia Market Size and Trends
Existing and Future Market Opportunity
Sarcopenia Report Key Strengths
10 years Forecast
The 7MM Coverage
Sarcopenia Epidemiology Segmentation
Key Cross Competition
Conjoint Analysis
Drugs Uptake and Key Market Forecast Assumptions
Sarcopenia Report Assessment
Current Treatment Practices
Unmet Needs
Pipeline Product Profiles
Market Attractiveness
Qualitative Analysis (SWOT and Conjoint Analysis)
Key Questions:
Market Insights
What was the Sarcopenia total market size, the market size by therapies, and market share (%) distribution in 2019, and how would it all look in 2032? What are the contributing factors for this growth?
What unmet needs are associated with the current treatment market of Sarcopenia?
What are the patents of emerging therapies for Sarcopenia?
Which drug is going to be the largest contributor by 2032?
What are the pricing variations among different geographies for approved and off-label therapies?
How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
Epidemiology Insights
What are the disease risks, burdens, and unmet needs of Sarcopenia? What will be the growth opportunities across the 7MM concerning the patient population of Sarcopenia?
What is the historical and forecasted Sarcopenia patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
Why do only limited patients appear for diagnosis?
Which country is more prevalent for Sarcopenia and why?
What factors are affecting the diagnosis of the indication?
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies
What are the current options for treating Sarcopenia? What are the current guidelines for treating Sarcopenia in the US and Europe?
How many companies are developing therapies for treating Sarcopenia?
How many emerging therapies are in the mid-stage and late stage of development for treating Sarcopenia?
What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies?
What are the key designations that have been granted for the emerging therapies for Sarcopenia?
Patient acceptability in terms of preferred treatment options as per real-world scenarios?
What are the country-specific accessibility issues of expensive, recently approved therapies? Focus on reimbursement policies.
What are the 7MM historical and forecasted markets of Sarcopenia?
Reasons to Buy:
The report will help develop business strategies by understanding the latest trends and changing treatment dynamics driving the Sarcopenia Market.
Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
To understand the existing market opportunity in varying geographies and the growth potential over the coming years.
Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
Identifying strong upcoming players in the market will help devise strategies that will help get ahead of competitors.
Detailed analysis and ranking of potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
Highlights of Access and Reimbursement policies of approved therapies, barriers to accessibility of off-label expensive therapies, and patient assistance programs.
To understand the perspective of Key Opinion Leaders around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.
Frequently Asked Questions
1. What is the forecast period covered in the report?
The Sarcopenia Epidemiology and Market Insight report for the 7MM covers the forecast period from 2023 to 2032, providing a projection of market dynamics and trends during this timeframe.
2. What are the challenges faced by the sarcopenia treatment market?
Challenges in the sarcopenia treatment market may include the need for more standardized diagnostic criteria, a lack of awareness among both healthcare professionals and the general population, and the complex interplay of factors contributing to sarcopenia. Overcoming these challenges is essential for the successful development and implementation of effective treatments.
3. Who are the key players in the Sarcopenia market?
The Sarcopenia market is quite robust. The major players like MyMD Pharmaceuticals, Inc., Biophytis, ImmunoForge, Oncocross, Rejuvenate Biomed, Mirscience Therapeutics, Turn Biotechnologies, Inc., NMD Pharma, and others are currently developing drugs for the treatment of Sarcopenia.
4. How is the market size estimated in the forecast report?
The market size is estimated through data analysis, statistical modeling, and expert opinions. It may consider factors such as incident cases, treatment costs, revenue generated, and market trends.
5. What is the key driver of the Sarcopenia market? What is the expected impact of emerging therapies or advancements in Sarcopenia treatment on the market?
The increase in diagnosed prevalent cases of Sarcopenia and launch of emerging therapies are attributed to be the key drivers for increasing Sarcopenia market. Introducing new therapies, advancements in diagnostic techniques, and innovations in treatment approaches can significantly impact the Sarcopenia treatment market. Market forecast reports may provide analysis and predictions regarding the potential impact of these developments.
6. Does the report provide insights into the competitive landscape of the market?
The market forecast report may include information on the competitive landscape, profiling key market players, their product offerings, partnerships, and strategies, and helping stakeholders understand the competitive dynamics of the Sarcopenia market.
Table of Contents
1. Key Insights
2. Report Introduction
3. Sarcopenia Market Overview at a Glance
3.1. Market Share (%) Distribution by Therapies of Sarcopenia in 2019
3.2. Market Share (%) Distribution by Therapies of Sarcopenia in 2032
4. Epidemiology and Market Methodology of Sarcopenia
5. Executive Summary of Sarcopenia
6. Key Events
7. Disease Background and Overview of Sarcopenia
7.1. Introduction
7.2. Definition and Classification
7.3. Causes
7.4. Risk Factors
7.5. Pathophysiology
7.6. Biomarkers
7.7. Relevance to Other Disease States
7.8. Diagnosis
7.8.1. Diagnostic Guidelines
7.8.1.1. European Working Group on Sarcopenia in Older People (EWGSOP2) Guidelines
7.8.1.2. International Conference on Sarcopenia and Frailty Research (ICSFR)
7.8.1.3. Asian Working Group for Sarcopenia (AWGS)
7.8.2. Diagnostic Algorithm
7.9. Treatment and Management
7.9.1. Treatment Guidelines
7.9.1.1. International Conference on Sarcopenia and Frailty Research (ICSFR)
7.9.2. Treatment Algorithm
8. Epidemiology and Patient Population
8.1. Key Findings
8.2. Assumption and Rationale of Sarcopenia: The 7MM
8.2.1. Prevalent Cases of Sarcopenia
8.2.2. Gender-specific Prevalent Cases of Sarcopenia
8.2.3. Age-specific Prevalent Cases of Sarcopenia
8.2.4. Severity-specific Prevalent Cases of Sarcopenia
8.3. Total Diagnosed Prevalent Cases of Sarcopenia in the 7MM
8.4. The United States
8.4.1. Total Diagnosed Prevalent Cases of Sarcopenia
8.4.2. Gender-specific Diagnosed Prevalent Cases of Sarcopenia
8.4.3. Age-specific Diagnosed Prevalent Cases of Sarcopenia
8.4.4. Severity-specific Diagnosed Prevalent Cases of Sarcopenia
8.5. EU4 and the UK
8.5.1. Germany
8.5.1.1. Total Diagnosed Prevalent Cases of Sarcopenia
8.5.1.2. Gender-specific Diagnosed Prevalent Cases of Sarcopenia
8.5.1.3. Age-specific Diagnosed Prevalent Cases of Sarcopenia
8.5.1.4. Severity-specific Diagnosed Prevalent Cases of Sarcopenia
8.5.2. France
8.5.2.1. Total Diagnosed Prevalent Cases of Sarcopenia
8.5.2.2. Gender-specific Diagnosed Prevalent Cases of Sarcopenia
8.5.2.3. Age-specific Diagnosed Prevalent Cases of Sarcopenia
8.5.2.4. Severity-specific Diagnosed Prevalent Cases of Sarcopenia
8.5.3. Italy
8.5.3.1. Total Diagnosed Prevalent Cases of Sarcopenia
8.5.3.2. Gender-specific Diagnosed Prevalent Cases of Sarcopenia
8.5.3.3. Age-specific Diagnosed Prevalent Cases of Sarcopenia
8.5.3.4. Severity-specific Diagnosed Prevalent Cases of Sarcopenia
8.5.4. Spain
8.5.4.1. Total Diagnosed Prevalent Cases of Sarcopenia
8.5.4.2. Gender-specific Diagnosed Prevalent Cases of Sarcopenia
8.5.4.3. Age-specific Diagnosed Prevalent Cases of Sarcopenia
8.5.4.4. Severity-specific Diagnosed Prevalent Cases of Sarcopenia
8.5.5. The UK
8.5.5.1. Total Diagnosed Prevalent Cases of Sarcopenia
8.5.5.2. Gender-specific Diagnosed Prevalent Cases of Sarcopenia
8.5.5.3. Age-specific Diagnosed Prevalent Cases of Sarcopenia
8.5.5.4. Severity-specific Diagnosed Prevalent Cases of Sarcopenia
8.6. Japan
8.6.1. Total Diagnosed Prevalent Cases of Sarcopenia
8.6.2. Gender-specific Diagnosed Prevalent Cases of Sarcopenia
8.6.3. Age-specific Diagnosed Prevalent Cases of Sarcopenia
8.6.4. Severity-specific Diagnosed Prevalent Cases of Sarcopenia
9. Patient Journey of Sarcopenia
10. Emerging Therapies
10.1. Key Cross Competition of Emerging Drugs
10.2. Sarconeos (BIO101): Biophytis
10.2.1. Product Description
10.2.2. Other Developmental Activities
10.2.3. Clinical Development
10.2.4. Clinical Trials Information
10.2.5. Safety and Efficacy
10.2.6. Product Profile
10.2.7. Analysts' Views
10.3. MYMD-1: MyMD Pharmaceuticals, Inc.
10.3.1. Product Description
10.3.2. Other Developmental Activities
10.3.3. Clinical Development
10.3.4. Clinical Trials Information
10.3.5. Safety and Efficacy
10.3.6. Product Profile
10.3.7. Analysts' Views
11. Sarcopenia: Market Analysis
11.1. Key Findings
11.2. Key Market Forecast Assumptions
11.3. Market Outlook
11.4. Conjoint Analysis
11.5. Total Market Size of Sarcopenia in the 7MM
11.6. Market Size of Sarcopenia by Therapies in the 7MM
11.7. Market Size of Sarcopenia in the United States
11.7.1. Total Market Size of Sarcopenia
11.7.2. Market Size of Sarcopenia by Therapies in the United States
11.8. Market Size of Sarcopenia in EU4 and the UK
11.8.1. Germany
11.8.1.1. Total Market Size of Sarcopenia
11.8.1.2. Market Size of Sarcopenia by Therapies
11.8.2. France
11.8.2.1. Total Market Size of Sarcopenia
11.8.2.2. Market Size of Sarcopenia by Therapies
11.8.3. Italy
11.8.3.1. Total Market Size of Sarcopenia
11.8.3.2. Market Size of Sarcopenia by Therapies
11.8.4. Spain
11.8.4.1. Total Market Size of Sarcopenia
11.8.4.2. Market Size of Sarcopenia by Therapies
11.8.5. The UK
11.8.5.1. Total Market Size of Sarcopenia
11.8.5.2. Market Size of Sarcopenia by Therapies
11.9. Market Size of Sarcopenia in Japan
11.9.1. Total Market Size of Sarcopenia
11.9.2. Market Size of Sarcopenia by Therapies in Japan
12. Key Opinion Leaders' Views
13. SWOT Analysis
14. Unmet Needs
15. Market Access and Reimbursement
15.1. The United States
15.1.1. Center for Medicare and Medicaid Services (CMS)
